Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.
Rapid progress towards understanding the molecular underpinnings of neurodegenerative disorders such as Alzheimer's disease is revolutionizing drug discovery for these conditions. Furthermore, the development of models for these disorders is accelerating efforts to translate insights related to neurodegenerative mechanisms into disease-modifying therapies. However, there is an urgent need for biomarkers to diagnose neurodegenerative disorders early in their course, when therapy is likely to be most effective, and to monitor responses of patients to new therapies. As research related to this need is currently most advanced for Alzheimer's disease, this Review focuses on progress in the development and validation of biomarkers to improve the diagnosis and treatment of Alzheimer's disease and related disorders.
Shaw
Leslie M
LM
Department of Pathology and Laboratory Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. shawlmj@mail.med.upenn.edu
Korecka
Magdalena
M
Clark
Christopher M
CM
Lee
Virginia M-Y
VM
Trojanowski
John Q
JQ
D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D015415:Biomarkers; D016903:Drug Monitoring; D006801:Humans; D019636:Neurodegenerative Diseases / Q000175:diagnosis* / Q000188:drug therapy*
D015415:Biomarkers